Pharmaceuticals
turnover in the nine months was £12,996 million, up 4% AER, 1%
CER. Respiratory sales were up 23% AER, 18% CER, to £2,189
million, on growth of Trelegy Ellipta and Nucala. HIV sales were up 4% AER, 1%
CER, to £3,597 million, with growth in Juluca and Dovato partly offset by a decline in
Triumeq. Sales of
Established Pharmaceuticals were £6,603 million, down 4% AER,
6% CER, including the impact of loss of exclusivity of Advair.
In the
US, sales grew 2% AER but declined 4% CER. Excluding Advair and Relvar/Breo Ellipta, impacted by
genericisation of the ICS/LABA market, growth was 15% AER, 9% CER.
Continued growth of Nucala,
Trelegy Ellipta and
Benlysta was offset by the
decline in Established Products including the loss of exclusivity
of Advair. In Europe, sales
grew 4% AER, 4% CER, with strong growth in Respiratory partly
offset by a decline in Established Pharmaceuticals. International
grew 7% AER, 6% CER, with growth in all therapy areas.
Respiratory
Total
Respiratory sales were up 23% AER, 18% CER, with strong growth in
all regions. Ellipta
product sales grew 17% AER, 13% CER, with Europe up 30% AER, 30%
CER and International up 33% AER, 30% CER on Trelegy and Relvar/Breo growth. Nucala was up 39% AER, 39% CER in
Europe and 65% AER, 56% CER in International. In the US,
Trelegy Ellipta and Nucala growth more than offset the
decline in Relvar/Breo
Ellipta on post generic
ICS/LABA price pressure.
Sales
of Nucala were £550
million in the nine months and grew 41% AER, 35% CER, continuing to
benefit from the global rollout of the product. US sales of
Nucala grew 37% AER, 29%
CER to £321 million.
Sales
of Ellipta products were up
17% AER, 13% CER to £1,639 million, driven by growth in Europe
and International regions. In the US, sales grew 8% AER, 2% CER,
reflecting continued competitive pricing pressures for ICS/LABAs,
post generic Advair. Sales
of Trelegy Ellipta
contributed £346 million globally in the nine months, driven
by an increase in US market share.
Relvar/Breo Ellipta sales were down 7% AER, 10% CER. This
was driven by the US, where Relvar/Breo Ellipta declined 31% AER, 35% CER as a
result of competitive pricing pressures and the impact of generic
Advair on the ICS/LABA
market. In Europe and International, Relvar/Breo Ellipta continued to grow, up 14% AER,
14% CER in Europe, and 23% AER, 21% CER in
International.
HIV
HIV
sales grew 4% AER, 1% CER to £3,597 million in the nine
months. The dolutegravir franchise grew 7% AER, 3% CER, delivering
sales of £3,425 million. The remaining portfolio, with sales
of £172 million (5% of total HIV sales), declined 26% AER, 26%
CER and reduced the overall HIV growth by two percentage
points.
Sales
of dolutegravir products were £3,425 million, with
Triumeq and Tivicay delivering sales of £1,911
million and £1,236 million, respectively. The two-drug
regimens, Juluca and
Dovato, delivered sales of
£278 million in the nine months with combined growth more than
offsetting the decline in the three-drug regimen, Triumeq, as the business transitions to
the new portfolio.
In the
US, following the launch of Dovato in April 2019, combined sales of
the two-drug regimens were £234 million. US dolutegravir sales
grew 5% AER but declined 1% CER, reflecting a year-on-year share
decline as the business transitions to the new two-drug portfolio,
partly offset by a net price benefit. In Europe, Dovato and Juluca reported combined sales of
£40 million, and total dolutegravir sales grew 1% AER, 1% CER,
with growth in market share more than offsetting price erosion and
the timing of clawback payments. International performed strongly
with total dolutegravir sales growth of 27% AER, 26% CER, driven by
Tivicay and Triumeq.
Oncology
Sales
of Zejula, were £163
million in the period from the date of acquisition, comprising
£97 million in the US and £66 million in
Europe.
Immuno-inflammation
Sales
of Benlysta in the nine
months were up 32% AER, 26% CER to £443 million, including
sales of the sub-cutaneous formulation of £189 million. In the
US, Benlysta grew 29% AER,
22% CER to £387 million.
Established Pharmaceuticals
Sales
of Established Pharmaceuticals in the nine months were £6,603
million, down 4% AER, 6% CER.
Established
Respiratory products declined 7% AER, 9% CER to £2,935
million, with the decline in Advair/Seretide partly offset by higher
sales of Ventolin
and allergy
products. In the US, a
generic version of Advair
was launched in February, resulting in a 50% AER, 53% CER decline
in the nine months. In Europe, Seretide sales were down 15% AER, 15%
CER to £383 million, reflecting continued competition from
generic products and the transition of the Respiratory portfolio to
newer products. In International, sales of Seretide grew 1% AER but were flat at
CER. Globally, Ventolin
grew by 36% AER, 32% CER, driven by the strong uptake of an
authorised generic version in the US.
The
remainder of the Established Pharmaceuticals portfolio declined 2%
AER, 3% CER to £3,668 million, with Lamictal down 8% AER, 11% CER to
£421 million on generic competition in the US and
International, partly offset by growth in Augmentin in the nine months and a
European Relenza
tender.
|